In November 2023, the Food and Drug Administration (FDA) approved Zepbound (tirzepatide) for long-term weight management. Tirzepatide has been approved for treating type 2 diabetes under the trade ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and weight-loss tirzepatide injection products (Mounjaro and ...

Shortly after the OFA filed its lawsuit, the FDA said it would review its decision to remove Lilly’s tirzepatide products from its shortage list—though the agency ultimately stuck by its ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Mounjaro (tirzepatide) is a prescription drug used to help manage blood sugar levels in adults with type 2 diabetes. Mounjaro comes as an injection that’s given under your skin. This medication ...

The FDA announced that the tirzepatide injection shortage is resolved ... and has ended as manufacturing capacity and product availability are sufficient to meet national demand.

Availability of services: Weight management services are ... be safely implemented within 3 months because there is insufficient capacity to deliver tirzepatide in primary care. To meet this resource ...

According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...

Weight-loss injection Mounjaro, also known as tirzepatide, will be rolled out on the NHS gradually over a 12-year period, starting this year, but many eligible patients will have to wait.

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...